• Product NameMK-5108 (VX-689)
• Brief DescriptionInhibitors
• Purification98.00%
• Biological ActivityMK-5108 (VX-689) is a highly selective Aurora A inhibitor with IC50 of 0.064 nM and is 220- and 190-fold more selective for Aurora A than Aurora B/C, while it inhibits TrkA with less than 100-fold selectivity. Phase 1.
• Target NameAurora Kinase inhibitor
• CAS No. 1010085-13-8
• Calculated MW 461.94
• Formulation C22H21ClFN3O3S
• Storage 3 years -20˚C powder;2 years -80˚C in solvent;

• Research Area:Cancer
  SMILES:OC(=O)[C@@]1(CC2=CC=CC(NC3=NC=CS3)=N2)CC[C@@H](CC1)OC1=C(F)C(Cl)=CC=C1 |r,c:7,13,16,26,30,32,t:5,11|
  Pathways:Cell Cycle/Checkpoint; Chromatin/Epigenetic
  Receptor:Aurora A
  Boling pt:
  Melting pt:
  Solubility:DMSO:92 mg/mL (199.16 mM)Ethanol:<1 mg/mL (<1 mM)Water<1 mg/mL (<1 mM)
  Appearance:
  Remark:For obtaining a higher solubility , please warm the tube at 37 ˚C and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 ˚C for several month.

1. Shimomura T, et al. Mol Cancer Ther. 2010, 9(1), 157-166.

• Flow Cytometry (FCM) General Protocol
• Immunofluorescence(IC)
• Immunohistochemistry(Polymer)
• Western Blotting